“Its drug manufacturing technology aligns with the Bank’s mission of harnessing innovation. Our investment of £6 million, as part of a larger total funding package, is a major step forward for the company as it accelerates the pace to develop treatments that will ultimately provide great relief to patients living with a range of conditions.
“We are proud to support this innovative company achieve its ambitions to deliver treatment to patients on a global scale."
Key Information
Alignment to the United Nation's Sustainable Development Goals
Good Health and Well-being
Decent Work and Economic Growth
Industry, Innovation and Infrastructure
Key Quote
Dr James McIlroy, EnteroBiotix chief executive, said: “This funding is further endorsement of EnteroBiotix and our vision of creating treatments that can have a global impact. Our facility in Bellshill is one of the most advanced of its kind in Europe and ensures safe and consistent in-house manufacturing.
“The support from the Scottish National Investment Bank means we can invest in our R&D programme, our team, and our facilities, all of which means we can develop treatments at a faster pace. Our long-term mission to transform the standard of care for patients suffering from high unmet clinical needs associated with the gut microbiome.
“Scotland’s life sciences sector is a growing industry, and with the Bank’s backing we can also contribute to improving skills and enhancing knowledge.”
